EUVIMEDEUVIMED entdecken
Crossref

Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors

Lev Gorfinkel iD, Emily M Harris iD, Catherine B Wall, Allison F O'Neill iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Lev Gorfinkel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Thrombopoietin, Thrombocytopenia, Receptors, Fc. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Romiplostim for chemotherapy‐induced thrombocytopenia (CIT) is not well‐studied in children. This single‐center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays ( p = 0.42) or dose reductions ( p > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsThrombopoietinThrombocytopeniaReceptors, FcNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansMaleFemaleChildChild, PreschoolRetrospective StudiesInfantAdolescentFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

chemotherapy‐induced thrombocytopeniapediatricromiplostimsolid tumor

Substanzen

romiplostimRecombinant Fusion ProteinsThrombopoietinReceptors, FcAntineoplastic Agents

Autor:innen und Institutionen

  • Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Lev Gorfinkel, Emily M Harris, Allison F O'Neill

Zitieren

APA

Gorfinkel, L., Harris, E. M., Wall, C. B., & O'Neill, A. F. (2025). Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32011

Vancouver

Gorfinkel L, Harris EM, Wall CB, O'Neill AF. Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32011

BibTeX
@article{Gorfinkel2025,
  author = {Gorfinkel, Lev and Harris, Emily M and Wall, Catherine B and O'Neill, Allison F},
  title = {Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32011}
}
Kostenlos starten →